Bionano Announces OGM Roadshow, TOUR, which Provides Education on the Company’s Workflow and Helps Build a Community of Users - Seite 2

Unless specifically noted otherwise, Bionano products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements of Bionano

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “might,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of TOUR to drive adoption of our OGM workflows or other genomic solutions; the potential of our OGM workflows or other genomic solutions to be useful in research applications such as hematological malignancies, genetic disease, and cell bioprocessing; the ability of our OGM workflows and other genomic solutions to offer new insights and address critical gaps left unanswered by other genome analysis products; and execution of our stated strategies and plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and potential future bank failures, the ongoing Ukraine-Russian conflict, and related sanctions, and the COVID-19 pandemic, on our business and the global economy; the failure TOUR to drive adoption of our OGM workflows and other genomic solutions; the failure of our OGM workflows or other genomic solutions to be useful in research applications such as hematological malignancies, genetic disease, and cell bioprocessing; the failure of our OGM workflows and other genomic solutions to offer new insights and address critical gaps left unanswered by other genome analysis products; execution of our stated strategies and plans; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern”; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.